+

WO1997048370A3 - Vaccins comprenant des genes de synthese - Google Patents

Vaccins comprenant des genes de synthese Download PDF

Info

Publication number
WO1997048370A3
WO1997048370A3 PCT/US1997/010517 US9710517W WO9748370A3 WO 1997048370 A3 WO1997048370 A3 WO 1997048370A3 US 9710517 W US9710517 W US 9710517W WO 9748370 A3 WO9748370 A3 WO 9748370A3
Authority
WO
WIPO (PCT)
Prior art keywords
synthetic
codons
polynucleotides
expression
molecules
Prior art date
Application number
PCT/US1997/010517
Other languages
English (en)
Other versions
WO1997048370A2 (fr
Inventor
John W Shiver
Mary Ellen Davies
Daniel C Freed
Margaret A Liu
Helen C Perry
Original Assignee
Merck & Co Inc
John W Shiver
Mary Ellen Davies
Daniel C Freed
Margaret A Liu
Helen C Perry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614943.0A external-priority patent/GB9614943D0/en
Priority claimed from GBGB9614942.2A external-priority patent/GB9614942D0/en
Application filed by Merck & Co Inc, John W Shiver, Mary Ellen Davies, Daniel C Freed, Margaret A Liu, Helen C Perry filed Critical Merck & Co Inc
Priority to JP10503267A priority Critical patent/JP2000516445A/ja
Priority to EP97931230A priority patent/EP0912607A2/fr
Priority to AU34918/97A priority patent/AU728422B2/en
Publication of WO1997048370A2 publication Critical patent/WO1997048370A2/fr
Publication of WO1997048370A3 publication Critical patent/WO1997048370A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des polynucléotides de synthèse comprenant une séquence d'ADN codant un peptide ou une protéine. La séquence d'ADN des polypeptides de synthèse comprend des codons optimisés pour une expression chez un hôte non homologue. L'invention est illustrées par des molécules d'ADN de synthèse codant env du VIH ainsi que des modifications d'env du VIH. Les codons des molécules de synthèse comprennent les codons préférés des cellules hôtes prévues. Les molécules de synthèse fournissent des formes préférées de matériel génétique étranger. On peut utiliser les molécules de synthèse en tant que vaccins polynucléotidiques procurant une immunoprophylaxie contre une infection à VIH par un anticorps neutralisant et une immunité à médiation cellulaire. Cette invention présente des polynucléotides qui, lorsqu'ils sont introduits directement dans un vertébré in vivo, notamment des mammifères primates et des sujets humains, induisent l'expression de protéines codées chez l'animal.
PCT/US1997/010517 1996-06-21 1997-06-17 Vaccins comprenant des genes de synthese WO1997048370A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP10503267A JP2000516445A (ja) 1996-06-21 1997-06-17 合成遺伝子を含むワクチン
EP97931230A EP0912607A2 (fr) 1996-06-21 1997-06-17 Vaccins comprenant des genes de synthese
AU34918/97A AU728422B2 (en) 1996-06-21 1997-06-17 Vaccines comprising synthetic genes

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US2016696P 1996-06-21 1996-06-21
US2016596P 1996-06-21 1996-06-21
US60/020,166 1996-06-21
US60/020,165 1996-06-21
GBGB9614943.0A GB9614943D0 (en) 1996-07-16 1996-07-16 Vaccines comprising synthetic genes
GB9614942.2 1996-07-16
GBGB9614942.2A GB9614942D0 (en) 1996-07-16 1996-07-16 Synthetic HIV ENV genes
GB9614943.0 1996-07-16

Publications (2)

Publication Number Publication Date
WO1997048370A2 WO1997048370A2 (fr) 1997-12-24
WO1997048370A3 true WO1997048370A3 (fr) 1998-03-26

Family

ID=27451496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/010517 WO1997048370A2 (fr) 1996-06-21 1997-06-17 Vaccins comprenant des genes de synthese

Country Status (5)

Country Link
EP (1) EP0912607A2 (fr)
JP (1) JP2000516445A (fr)
AU (1) AU728422B2 (fr)
CA (1) CA2258568A1 (fr)
WO (1) WO1997048370A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
CA2358385C (fr) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
WO2000029561A2 (fr) * 1999-03-29 2000-05-25 Statens Serum Institut Methode de production d'une construction de sequence de nucleotides a base de codons optimises, pour un vaccin genetique contre le vih, a partir d'un isolat primaire et precoce du vih, et constructions de l'enveloppe synthetique bx08
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP1200622A4 (fr) 1999-07-06 2004-12-22 Merck & Co Inc Vaccin contre le vih comprenant un adenovirus vehiculant le gene gag
EP2278022A3 (fr) 1999-11-01 2011-05-18 Novartis Vaccines and Diagnostics, Inc. Vecteurs d'expression, systèmes de transfection et procédé d'utilisation correspondant
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
DE10053781B4 (de) * 2000-10-30 2008-07-03 Geneart Ag Kernexportreportersystem
ATE291925T1 (de) * 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) * 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
EP1578766B1 (fr) 2002-12-03 2013-02-13 University of Massachusetts Vaccins polyvalents a adn contre la glycoproteine du hiv-1 primaire et procedes de vaccination
EP1708745B1 (fr) 2003-12-23 2012-04-18 Arbor Vita Corporation Anticorps pour des souches oncogenes du hpv et leurs methodes d'utilisation
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
CA2925021A1 (fr) 2013-11-01 2015-05-07 Curevac Ag Arn modifie a proprietes immunostimulantes reduites
RS66380B1 (sr) 2014-04-23 2025-02-28 Modernatx Inc Vakcine nukleinske kiseline
WO2020190750A1 (fr) 2019-03-15 2020-09-24 Modernatx, Inc. Vaccins à base d'arn contre le vih
CN112735525B (zh) * 2021-01-18 2023-12-26 苏州科锐迈德生物医药科技有限公司 一种基于分治法的mRNA序列优化的方法与装置

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016737A1 (fr) * 1993-01-26 1994-08-04 Weiner David B Compositions et procedes d'administration de matieres genetiques
WO1995020660A2 (fr) * 1994-01-27 1995-08-03 University Of Massachusetts Medical Center Immunisation par inoculation d'une unite de transcription d'adn
WO1996021356A1 (fr) * 1995-01-13 1996-07-18 Vanderbilt University Procedes et compositions destines a induire des reponses immunitaires des muqueuses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン
WO1997011086A1 (fr) * 1995-09-22 1997-03-27 The General Hospital Corporation Expression de proteines a des hauts niveaux
WO1997031115A2 (fr) * 1996-02-22 1997-08-28 Merck & Co., Inc. Genes synthetiques du vih

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016737A1 (fr) * 1993-01-26 1994-08-04 Weiner David B Compositions et procedes d'administration de matieres genetiques
WO1995020660A2 (fr) * 1994-01-27 1995-08-03 University Of Massachusetts Medical Center Immunisation par inoculation d'une unite de transcription d'adn
WO1996021356A1 (fr) * 1995-01-13 1996-07-18 Vanderbilt University Procedes et compositions destines a induire des reponses immunitaires des muqueuses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン
WO1997011086A1 (fr) * 1995-09-22 1997-03-27 The General Hospital Corporation Expression de proteines a des hauts niveaux
WO1997031115A2 (fr) * 1996-02-22 1997-08-28 Merck & Co., Inc. Genes synthetiques du vih

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B. WANG ET AL.: "Gene inoculation generates immune responses against human immunodeficiency virus type 1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, 1 May 1993 (1993-05-01), WASHINGTON US, pages 4156 - 4160, XP000608482 *
DATABASE WPI Section Ch Week 9641, Derwent World Patents Index; Class B04, AN 96-408330, XP002036840 *
K. OKUDA ET AL.: "Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV typr 1 env and rev gene products", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, no. 8, August 1995 (1995-08-01), pages 933 - 943, XP002036839 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Also Published As

Publication number Publication date
AU728422B2 (en) 2001-01-11
WO1997048370A2 (fr) 1997-12-24
CA2258568A1 (fr) 1997-12-24
AU3491897A (en) 1998-01-07
JP2000516445A (ja) 2000-12-12
EP0912607A2 (fr) 1999-05-06

Similar Documents

Publication Publication Date Title
WO1997048370A3 (fr) Vaccins comprenant des genes de synthese
WO2001062794A3 (fr) Nouveaux canaux calciques humains 18607
WO1998034640A3 (fr) Genes synthetiques du gag hiv
CA2158455A1 (fr) Chimeres immunogenes comportant des sequences d'acides nucleiques codant pour les peptides de la sequence du signal du reticule endoplasmique et au moins un autre peptide, et leurs ustilisations dans les vaccins et le traitement des maladies
WO2001072976A3 (fr) 32142, 21481, 25964, 21686, nouvelles molecules deshydrogenases humaines et utilisations
NZ331161A (en) Synthetic HIV genes encoding envelope (env) proteins
WO2001014416A3 (fr) Genes synthetiques humains du virus de papillome
WO2002000722A3 (fr) 48000 et 52920, nouveaux canaux calciques humains et leurs utilisations
WO2002006302A3 (fr) Nouvelles molecules humaines de phospholipases c, 16816 et 16839, et utilisations correspondantes
WO2002026803A3 (fr) 22108 et 47916, nouveaux membres de la famille des thioredoxines humaines et leurs applications
WO2002016589A3 (fr) 44589, nouveau membre de la famille des transporteurs abc humains, et ses utilisations
WO1998042847A3 (fr) Proteines a capside principale de papillomavirus et leur utilisation a des fins de diagnostic, de therapie et de vaccination
WO1999009177A3 (fr) Papillomavirus, agents permettant de les mettre en evidence et de traiter des affections induites par lesdits papillomavirus
WO2001075076A3 (fr) 33167, nouvelle hydrolase humaine, et utilisations associees
WO2001066764A3 (fr) 16835, un nouvel element de la famille c de phospholipase humaine et utilisations correspondantes
WO2002029042A3 (fr) Molecules 48120, 23479, et 46689, nouvelles hydrolases humaines et leurs applications
WO2001077329A3 (fr) 12303, molecule twik humaine et utilisations correspondantes
WO2002008395A3 (fr) 42755, une nouveau membre de la famille de la methyl-transferase humaine et ses applications
WO2002024743A3 (fr) 55063, nouveau membre de la famille nmda humaine et ses applications
WO2002050256A8 (fr) 53010, nouveau membre de la famille des carboxylesterases humaines et utilisations
WO2002026804A3 (fr) 84241, nouveau membre humain de la famille ring finger et utilisation de celui-ci
WO2001096375A3 (fr) La 33358, nouveau membre de la famille humaine des ankyrines et ses utilisations
WO2002026983A3 (fr) 56115, nouveau canal potassium humain associe a twik et applications de celui-ci
WO2003048188A3 (fr) 15603, membre de la famille des canaux ioniques humains, et ses utilisations
WO2002059314A3 (fr) 52020, nouvel antigene associe a un melanome humain et ses utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1997931230

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2258568

Country of ref document: CA

Ref country code: CA

Ref document number: 2258568

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997931230

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997931230

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载